Efficacy of infliximab in patient with unfavorable clinical course of juvenile rheumatoid arthritis
<i>The article presents a case report of aggressive rapidly progressive severe polyarticular juvenile rheumatoid arthritis (JRA) resistant to standard immunosuppressive treatment. Patient with extra-early (up to 6 months) arthritis was successfully treated with genetically engineered biological agent infliximab. Pain decreased significantly after first injection of a drug, the second injection resulted in decrease of laboratory activity, third one completely stopped exudative lesion of joints, morning stiffness, and restored functional activity of a child. Thus, after 6 months the disease was transferred to inactive phase, motions of joints restored, there was no need in nonsteroid anti-inflammatory drugs. Cardiovascular symptoms stopped as well. The case report showed high efficacy of tumor necrotizing factor </i> α <i>blocker infliximab in patients with aggressive clinical course and markers of unfavorable prognosis at very early stages of JRA before irreversible lesions of joints happen.</i>